{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-014358","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2023-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.038550+00:00","generated_at":"2026-06-19T00:29:32.065854+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ABVC BioPharma secures $3.175M investment from Lind Partners via convertible note and warrant","bullets":["Issued $3.704M secured convertible note to Lind Global Fund II, LP for net proceeds of $3.175M; initial conversion price $1.05/share.","Also issued warrant to purchase up to 5,291,667 shares at $1.05/share; monthly payments start after 6 months, can be in cash or stock.","Proceeds to fund Phase II trials for Vitargus (retinal surgery device) and ABV-1505 (ADHD drug).","Note carries no interest; cash payments include 5% premium; default triggers 120% of outstanding principal.","Placement agent Allele Capital Partners receives 6% cash fee and warrants for 6% of shares issuable."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-014358","json":"https://secwatch.observer/filing/0001213900-23-014358.json","markdown":"https://secwatch.observer/filing/0001213900-23-014358.md","text":"https://secwatch.observer/filing/0001213900-23-014358.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/0001213900-23-014358-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/ea174178-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T00:29:32.065854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50637fb6af963b491e82522543b2e08cbfb10bfa","claim":"ABVC BIOPHARMA, INC. entered into Securities Purchase Agreement with Lind Global Fund II, LP valued at $3,704,167 (effective 2023-02-23).","evidence_excerpt":"On February 23, 2023, ABVC BioPharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Lind Global Fund II, LP (“Lind”), pursuant to which the Company would issue Lind a secured, convertible note in the principal amount of $3,704,167 (the “Offering”), for a purchase price of $3,175,000 (the “Note”), that is convertible into shares of the Company’s common stock at an initial conversion price of $1.05 per share, subject to adjustment (the “Note Shares”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/0001213900-23-014358-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Lind Global Fund II, LP"},{"label":"Value","value":"$3,704,167"},{"label":"Effective","value":"2023-02-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}